Acalabrutinib

Acalabrutinib (1420477-60-6) is a highly selective, potent (IC50 = 3nM), and irreversible inhibitor of Bruton’s tyrosine kinase (BTK) .1 Improved target selectivity (especially against TEC family kinases and EGFR) decreased the number of serious side effects observed with Ibrutinib.2 Acalabrutinib significantly inhibits BCR signaling, inhibits tumor proliferation, and reduces tumor burden.3 Clinically useful agent for treating B-cell cancers. BTK has also been shown to have a role in modulating the innate immune system, especially in dendritic cells and macrophages, suggesting a possible role in immunotherapy.4